SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
6-K
REPORT OF
FOREIGN ISSUER
Pursuant
to Rule 13a-16 or 15d-16 of
the
Securities Exchange Act of 1934
For
the month of April 2005
Commission
File Number 000-51122
pSivida
Limited
(Translation
of registrant’s name into English)
Level 12
BGC Centre
28 The
Esplanade
Perth WA
6000
(Address
of principal executive offices)
(Indicate
by check mark whether the registrant files or will file annual reports under
cover Form 20-F or Form 40-F).
Form 20-F
ý Form
40-F o
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule 101(b)(1):
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule 101(b)(7):
Indicate
by check mark whether the registrant by furnishing the information contained in
this Form is also thereby furnishing the information to the Commission pursuant
to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes
o No
ý
If "Yes"
is marked, indicate below the file number assigned to the registrant in
connection with Rule 12g3-2(b): 82- ___.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant,
pSivida Limited, has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
Date:
April 4, 2005
| pSivida Limited | ||
| |
|
|
| By: | /s/ Aaron Finlay | |
|
Aaron Finlay | ||
| Chief Financial Officer and Company Secretary | ||
EXHIBIT
INDEX
|
EXHIBIT
99.1: |
Webcast
of pSivida Presentation Stephens Inc Nanotechnology Investors
Conference |
- 2
- -
ASX/MEDIA
RELEASE |
4th
April 2005 |
Webcast
of pSivida Presentation
Stephens
Inc Nanotechnology Investors Conference
Global
nanotechnology company pSivida Limited (ASX:PSD,
NASDAQ:PSDV, Xetra:PSI), is
pleased to announce that its Managing Director Mr Gavin Rezos will be presenting
at the Stephens Inc Nanotechnology Investors Conference on Tuesday
5th
April at
9.00am. The
conference will be held at The Ritz-Carlton, Pasadena, California.
A link to
the live web cast and recording of pSivida’s presentation will be available on
pSivida’s website http://www.psivida.com/News/Presentations.asp.
For
further details on the conference visit www.stephens.com
-ENDS-
Released
by:
|
In
Australia: |
In
US: |
|
Josh
Mann, CFA |
Beverly
Jedynak |
|
Investor
Relations |
President |
|
pSivida
Limited |
Martin
E. Janis & Company, Inc. |
|
Tel:
+ 61 8 9226 5099 |
Tel:
312-943-1100 ext. 12 |
|
joshuamann@psivida.com |
bjedynak@janispr.com |
Ticker
Symbols
|
Australian
Stock Exchange |
:
PSD |
|
NASDAQ |
:
PSDV |
|
Frankfurt
Stock Exchange (Xetra) |
:
PSI |
NOTES
TO EDITORS:
pSivida
Limited
pSivida
is a global nanotechnology company committed to the biomedical sector and the
development of products in healthcare. The company’s focus is the development
and commercialisation of a modified form of silicon (porosified or
nano-structured silicon) known as BioSilicon™. As a new and exciting
biocompatible and biodegradable material, BioSilicon offers multiple potential
applications across the high growth healthcare sector, including controlled
release drug delivery, targeted cancer therapies (including brachytherapy and
localized chemotherapy), tissue engineering and orthopedics. Potential
diagnostics applications are being developed through its subsidiary AION
Diagnostics Limited.
pSivida
owns the intellectual property rights to BioSilicon, royalty free for use in or
on humans and animals. The IP portfolio consists of 24 patent families, 26
granted patents and over 80 patent applications. The core patent, which
recognises BioSilicon as a biomaterial was granted in the UK in 2000 and in the
US in 2001.
pSivida
is listed on NASDAQ (PSDV), the
Australian Stock Exchange (PSD) and in
Germany on the Frankfurt Stock Exchange on the XETRA system (German Symbol:
PSI. Securities Code (WKN) 358705).
pSivida’s shares also trade in the United Kingdom on the OFEX International
Market Service (IMS) under the ticker symbol PSD.
The
Company’s strategic partner and largest shareholder is the QinetiQ group, the
largest science and technology company in Europe. QinetiQ is the former UK
government Defence Evaluation Research Agency and was instrumental in
discovering BioSilicon. pSivida enjoys a strong relationship with QinetiQ having
access to its cutting edge research and development facilities. For more
information on QinetiQ visit www.qinetiq.com.
For more
information visit www.psivida.com
This
document contains forward-looking statements that involve risks and
uncertainties. Although we believe that the expectations reflected in such
forward-looking statements are reasonable at this time, we can give no assurance
that such expectations will prove to be correct. Given these uncertainties,
readers are cautioned not to place undue reliance on such forward-looking
statements. Actual results could differ materially from those anticipated in
these forward-looking statements due to many important factors including: our
failure to develop applications for BioSilicon due to regulatory, scientific or
other issues. Other reasons are contained in cautionary statements in the
Registration Statement on Form 20-F filed with the U.S. Securities and Exchange
Commission, including, without limitation, under Item 3.D, "Risk Factors"
therein. We do not undertake to update any oral or written forward-looking
statements that may be made by or on behalf of pSivida.